ICH Takes Flexible Approach On Presenting Benefit-Risk Assessment In Drug Submissions
Executive Summary
The International Council for Harmonisation's final guidance on standardizing benefit-risk information in drug submissions is expected to support regulatory decision-making through a more consistent description of information.
You may also be interested in...
ICH: India, Mexico And Russia Among New Observers; Benefit-Risk Guideline Adopted
India, Mexico, Singapore, South Korea, Russia and Taiwan are among the latest countries to become observers at the International Council for Harmonisation, which has been seeking to establish itself as a 'truly global platform' since undergoing major structural reforms last year1.
ICH Consults On Standardizing Benefit-Risk Information In CTD Drug Submissions
The International Conference on Harmonisation is inviting feedback on proposed changes to how drug companies should present the benefits and risks of their drug in Module 2 of the common technical document (CTD)1,2. The proposed changes aim to standardize the presentation of benefit-risk information in regulatory submissions using the CTD format.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.